Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics
July 2023
Cancer is an abnormal state of cells where they undergo uncontrolled proliferation and produce aggressive malignancies that causes millions of deaths every year. With the new understanding of the molecular...
Share article
Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis
June 2018
As the most commonly occurring cancer in women worldwide, breast cancer poses a formidable public health challenge on a global scale. Breast cancer consists of a group of biologically and molecularly...
Share article
Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine
January 2024
CRISPR/Cas9 is an effective gene editing tool with broad applications for the prevention or treatment of numerous diseases. It depends on CRISPR (clustered regularly interspaced short palindromic repeats)...
Share article
Age-related macular degeneration: Epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy
January 2022
Age-related macular degeneration (AMD) is a complex eye disorder and is the leading cause of incurable blindness worldwide in the elderly. Clinically, AMD initially affects the central area of retina...
Share article
The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases
May 2021
The nuclear factor kappa B (NF-kB) family of transcription factors plays an essential role as stressors in the cellular environment, and controls the expression of important regulatory genes such as...
Share article
The m6A regulator KIAA1429 stabilizes RAB27B mRNA and promotes the progression of chronic myeloid leukemia and resistance to targeted therapy
March 2024
Chronic myeloid leukemia (CML) is a common adult leukemia. Both the acute phase of the disease and the adverse effects of anti-cancer treatments can lead to a poor prognosis. The N6-methyladenine (m6A)...
Share article
Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine
May 2022
Among the gynecological cancers, ovarian cancer is the most lethal. Its therapeutic options include a combination of chemotherapy with platinum-based compounds and cytoreductive surgery. Most ovarian...
Share article
Bone Morphogenetic Protein (BMP) signaling in development and human diseases
September 2014
Bone Morphogenetic Proteins (BMPs) are a group of signaling molecules that belongs to the Transforming Growth Factor-β (TGF-β) superfamily of proteins. Initially discovered for their ability to induce...
Share article
Deregulated miRNA clusters in ovarian cancer: Imperative implications in personalized medicine
November 2022
Ovarian cancer (OC) is one of the most common and fatal types of gynecological cancer. OC is usually detected at the advanced stages of the disease, making it highly lethal. miRNAs are single-stranded,...
Share article
Canonical and noncanonical Wnt signaling: Multilayered mediators, signaling mechanisms and major signaling crosstalk
January 2024
Wnt signaling plays a major role in regulating cell proliferation and differentiation. The Wnt ligands are a family of 19 secreted glycoproteins that mediate their signaling effects via binding to Frizzled...
Share article
Pretreating and normalizing metabolomics data for statistical analysis
May 2024
Metabolomics as a research field and a set of techniques is to study the entire small molecules in biological samples. Metabolomics is emerging as a powerful tool generally for precision medicine. Particularly,...
Share article
Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
January 2023
Molecular target inhibitors have been regularly approved by Food and Drug Administration (FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and metabolism. The RAS–RAF–MEK–ERK...
Share article
Mechanism of PARP inhibitor resistance and potential overcoming strategies
January 2024
PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose) polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by obstructing the DNA single-strand...
Share article
A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)
November 2023
Over the past few decades, advances in immunological knowledge have led to the identification of novel immune checkpoints, reinvigorating cancer immunotherapy. Immunotherapy, represented by immune checkpoint...
Share article
Studies on the fat mass and obesity-associated (FTO) gene and its impact on obesity-associated diseases
November 2023
Obesity has become a major health crisis in the past ∼50 years. The fat mass and obesity-associated (FTO) gene, identified by genome-wide association studies (GWAS), was first reported to be positively...
Share article
Temozolomide resistance in glioblastoma multiforme
September 2016
Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ. This is due primarily...
Share article
Share article
Colony-stimulating factor-1 receptor inhibition combined with paclitaxel exerts effective antitumor effects in the treatment of ovarian cancer
May 2024
Ovarian cancer is the tumor with the highest mortality among gynecological malignancies. Studies have confirmed that paclitaxel chemoresistance is associated with increased infiltration of tumor-associated...
Share article
Share article
Circulating and non-circulating proteins and nucleic acids as biomarkers and therapeutic molecules in ovarian cancer
May 2023
Ovarian cancer is the second most fatal gynecological cancer. For the last decade or so significant use of non-circulating and circulating biomarkers has been highlighted. However, the study of such...
Share article
Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine
June 2017
With rapid advances in understanding molecular pathogenesis of human diseases in the era of genome sciences and systems biology, it is anticipated that increasing numbers of therapeutic genes or targets...
Share article
Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
May 2023
Continuous revision of the histologic and stage-wise classification of lung cancer by the World Health Organization (WHO) provides the foundation for therapeutic advances by promoting molecular targeted...
Share article
The recent advances and future perspectives of genetic compensation studies in the zebrafish model
March 2023
Genetic compensation is a remarkable biological concept to explain the genetic robustness in an organism to maintain its fitness and viability if there is a disruption occurred in the genetic variation...
Share article
Recombinant adeno-associated virus 8 vector in gene therapy: Opportunities and challenges
January 2024
In recent years, significant breakthroughs have been made in the field of gene therapy. Adeno-associated virus (AAV) is one of the most promising gene therapy vectors and a powerful tool for delivering...
Share article
Transcriptomic analysis identifies the neuropeptide cortistatin (CORT) as an inhibitor of temozolomide (TMZ) resistance by suppressing the NF-κB-MGMT signaling axis in human glioma
May 2024
Glioma is a common tumor originating in the brain that has a high mortality rate. Temozolomide (TMZ) is the first-line treatment for high-grade gliomas. However, a large proportion of gliomas are resistant...
Share article
